RegulationPriority Review (United States), Breakthrough Therapy (United States), Promising Innovative Medicine (United Kingdom), Priority Review (China)

Structure/Sequence

Molecular FormulaC14H21N5O2S

InChIKeyIUEWXNHSKRWHDY-PHIMTYICSA-N

CAS Registry1622902-68-4

Clinical Trials associated with Abrocitinib

NCT06807281

/ Not yet recruitingPhase 3

A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

Start Date03 Nov 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06899204

/ Not yet recruitingNot Applicable

A Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to ≤2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis

This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the United States.
The aim of this study is to measure the effectiveness of abrocitinib in a real-world setting in patients with moderate-to-severe atopic dermatitis, with inadequate response or intolerance to ≤2 biologic therapies.

Start Date30 Jun 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06807268

/ Not yet recruitingPhase 3

A 16-WEEK, MULTICENTER, INTERVENTIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ABROCITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.

Start Date16 Jun 2025

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Abrocitinib

100 Translational Medicine associated with Abrocitinib

100 Patents (Medical) associated with Abrocitinib

443

Literatures (Medical) associated with Abrocitinib

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated

Article

Author: Qin, Yu-Liang ; Sun, Dong-Jie ; Tu, Ying ; Tang, Jun-Ting ; Zhao, Wei-Jia

PURPOSE:

To investigate the potential genetic basis of Netherton syndrome (NS) through first- and second-generation DNA sequencing techniques. Additionally, we evaluated the therapeutic efficacy of Abrocitinib in NS patients.

MATERIALS AND METHODS:

We conducted whole-exome sequencing analysis on a pedigree comprising one affected individual with NS. Subsequently, the identified patient was treated with Abrocitinib, and clinical improvements in cutaneous manifestations were systematically assessed.

RESULTS:

Genetic analysis revealed that the patient harbored compound heterozygous mutations in the SPINK5 gene, including a missense mutation in exon 26 (c.2475G > T, p.Trp825Cys). Following six months of Abrocitinib therapy, the patient exhibited marked improvement in skin rash and overall disease severity.

CONCLUSIONS:

Our findings suggest that SPINK5 missense mutations may contribute to the pathogenesis of NS. Furthermore, Abrocitinib demonstrates promising therapeutic potential in the management of NS, warranting further investigation in larger clinical cohorts.

01 Jun 2025·PHARMACOLOGICAL RESEARCH

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update

Review

Author: Roskoski, Robert

Because of the deregulation of protein kinase action in many inflammatory diseases and cancer, the protein kinase family has become one of the most significant drug targets in the 21st century. There are 85 FDA-approved protein kinase antagonists that target about two dozen different enzymes and four of these drugs were approved in 2024 and a fifth was approved in 2025. Of these drugs, five target dual specificity protein kinases (MEK1/2), fourteen inhibit protein-serine/threonine protein kinases, twenty-one block nonreceptor protein-tyrosine kinases, and 45 target receptor protein-tyrosine kinases. The data indicate that 75 of these drugs are prescribed for the treatment of neoplasms. Seven drugs (abrocitinib, baricitinib, deucravacitinib, deuruxolitinib, ritlecitinib, tofacitinib, upadacitinib) are prescribed for the management of inflammatory diseases (atopic dermatitis, rheumatoid arthritis, psoriasis, alopecia areata, and ulcerative colitis). Of the 85 FDA-approved agents, about two dozen are used in the treatment of multiple diseases. The following four drugs received FDA approval in 2024 - deuruxolitinib (alopecia areata), ensartinib and lazertinib (non-small cell lung cancer), and tovorafenib (pediatric glioma) while mirdametinib was approved in 2025 for the treatment of type I neurofibromatosis (von Recklinghausen disease). Apart from netarsudil, temsirolimus, and trilaciclib, the approved protein kinase blockers are orally bioavailable. This article summarizes the physicochemical properties of all 85 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, ligand efficiency, lipophilic efficiency, polar surface area, and solubility. A total of 39 of the 85 FDA-approved drugs have a least one Lipinski rule of 5 violation.

31 May 2025·CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

Novel use of abrocitinib in refractory ulcerative panniculitis with vasculitis: a case report.

Letter

Author: Qiu, Sheng ; Ying, Zhenhua

News (Medical) associated with Abrocitinib

19 Nov 2024

·pharma.economictimes.indiatimes.com

Glenmark to focus on becoming branded company, says Glenn Saldanha

Mumbai: Glenmark is focusing on moving up the value chain to transform into a branded pharmaceutical company with a significant portion of its revenue coming from higher-margin branded products, having overcome a challenging period, its chairman and managing director Glenn Saldanha told ET. “I think we've come a long way… We had three, four difficult years,” he said, citing issues with the US Food and Drug Administration (FDA), the Department of Justice (DOJ) and some litigations. “Lots of challenges we faced… All that is behind us,” Saldanha added. “I think now things are much better. So, the platform is set to continue to scale and to grow faster.” On some analysts raising doubts about Glenmark’s way forward after the sale of Glenmark Life Sciences (GLS), its active pharmaceutical ingredient business, and some branded portfolios, Saldanha said, “We've done some portfolio rationalisation, and the GLS divestment was because our view was, given the changing dynamic in the generics business, we didn't find the need to keep the API business within our portfolio. The sale helped us to re-channelise our entire energies into becoming a branded company.” He said the “aggression and the passion” are intact and the company isn't going to slow down. “We will not give up (on) scale.” Glenmark has been cleaning up its balance sheet. It used the proceeds from GLS divestment to pare debt. It currently has a debt-to-equity ratio of 0.16%. The company halved its expenditure on R&D from $120-130 million per annum at its peak to about $60 million through a series of out-licensing deals. Saldanha said the company will record Rs 13,500-14,000 crore of revenues this year, growing at about 12%-15% CAGR, and reach about Rs 15,500 crore next year. Almost 65% of its revenues are coming from branded business, which gives the business stability from pricing pressures, he said. Glenmark ended FY24 with revenue of around Rs 10,944 crore in revenue with an Ebitda margin of 19%. India contributes one-third of its revenue, while the US accounts for 28% and Europe 12%. Saldanha said the company will increasingly focus on three therapeutic segments – respiratory, dermatology and oncology – for its branded business. In early January, Glenmark became the first Indian company to launch a biosimilar of anti-diabetic GLP-1 drug Liraglutide in the country. It has also announced a series of partnerships to bring innovative drugs including tie-ups with Jiangsu Alphamab Biopharmaceuticals and 3D Medicines for KN035 (Envafolimab) for multiple geographies around the world. It partnered with Pfizer to launch Abrocitinib, used for treating atopic dermatitis in India under the brand name Jabryus. It has entered into an agreement with BeiGene for marketing and distribution of Tislelizumab and Zanubrutinib in India. By Viswanath Pilla ,

AcquisitionLicense out/inDrug Approval

10 Sep 2024

·synapse.patsnap.com

Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application

Recently, the application for a new indication for Hengrui Medicine's Ivarmacitinib sulfate tablets has been accepted by the CDE for use in adult patients with severe alopecia areata. About IvarmacitinibIvarmacitinib is a second-generation JAK inhibitor that exerts anti-inflammatory and immunosuppressive biological effects by inhibiting JAK1 signaling. The drug features high selectivity, efficacy, and an extended plasma half-life, which enhances the therapeutic window. In January 2018, Hengrui reached an agreement with Arcutis to license the Ivarmacitinib project for treating immune system diseases; Arcutis obtained exclusive rights for the clinical development, registration, and marketing of Ivarmacitinib in the USA, EU, and Japan. Hengrui could receive up to $223 million in upfront and milestone payments, plus sales royalties. Currently, Ivarmacitinib has initiated multiple clinical studies in various fields, including ulcerative colitis and psoriatic arthritis, with most progressing to Phase III clinical trials. It has already submitted marketing applications for indications such as atopic dermatitis, ankylosing spondylitis, and rheumatoid arthritis. In June 2024, a Phase III randomized, double-blind, placebo-controlled study assessing the efficacy and safety of Ivarmacitinib sulfate tablets in adult patients with severe alopecia areata showed significant superiority of Ivarmacitinib over placebo in both 8mg and 4mg dose groups, demonstrating good long-term treatment safety and efficacy in patients with severe alopecia areata, without new safety signals compared to other JAK1 inhibitors. About JAK InhibitorsThe Janus kinase (JAK) family comprises non-receptor tyrosine kinases that are intimately associated with cytokine receptors, including four members: JAK1, JAK2, JAK3, and TYK2. JAKs are critical sensors for various cytokines and interferons. Upon cytokine binding to cell surface receptors, JAKs are activated, facilitating transmembrane phosphorylation, which in turn phosphorylates downstream signaling and transcription activation factors (STAT), forming dimers (pSTAT). pSTAT moves into the nucleus to bind with specific promoters and enhance gene expression. As selective inhibitors of JAK kinases, JAK inhibitors can regulate inflammatory signaling pathways, providing anti-inflammatory and immunoregulatory effects, thus treating autoimmune diseases. Several JAK inhibitors have been approved globally, with a continuously growing market. Key products include Novartis/Incyte’s Ruxolitinib, Pfizer’s Tofacitinib, Eli Lilly’s Baricitinib, and AbbVie’s Upadacitinib. The JAK inhibitor market in China started later, with approvals for Ruxolitinib and Tofacitinib in 2017 and Baricitinib in 2019. In June 2024, Dizal Pharma's Golidocitinib was approved by the NMPA for adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) who have undergone at least one line of systemic therapy, marking it as the first and only highly selective JAK1 inhibitor globally for the lymphoma field. According to incomplete statistics, there are currently about a hundred JAK drugs under research in China, with several in Phase III or beyond. Since 2022, several new JAK inhibitor products (Upadacitinib, Abrocitinib, Deucravacitinib, Ritlecitinib) have been approved one after another. The market is expected to experience accelerated growth, with Frost & Sullivan projecting that the Chinese JAK1 inhibitor market could grow to 48.1 billion yuan by 2030. About Alopecia AreataAlopecia Areata (AA) is a typical autoimmune disease, commonly believed to result from the destruction of hair follicle cells, either due to cytokines secreted by cytotoxic T cells (Tc cells) or directly through cellular damage in an inflammatory environment mediated by mononuclear cells. Clinically, AA can vary in severity and is categorized into patchy, reticular, ophiasis, central, diffuse, total, and universal alopecia. Among these, patchy alopecia represents the mildest form and is the easiest to recover from. Total alopecia involves the loss of all hair on the scalp, while the most severe, universal alopecia, results in the loss of all body hair. Approximately half of the patients experience recurrent episodes, which can persist for several years or even decades. The global prevalence of AA is about 0.1%, with a lifetime risk of 2%; according to an article published in the International Journal of Dermatology, there are around 147 million people worldwide suffering from AA. Epidemiological studies suggest that the prevalence in China is 0.27%; Frost & Sullivan estimated that in 2020 there were approximately 3.812 million people with AA in China, expected to rise to 4.649 million by 2030. Treatment approaches for AA include general treatment, topical therapies, and systemic therapies. Topical treatments include corticosteroids, local immunotherapy, minoxidil, calcineurin inhibitors, and prostaglandin analogs. Systemic treatment primarily involves systemic corticosteroids, with immunosuppressants such as cyclosporine being used as non-first-line medications. According to the "Chinese Guidelines for Diagnosis and Treatment of Alopecia Areata (2019)", the clinical therapies for AA mainly divide into topical and systemic treatment, predominantly utilizing corticosteroids and broad-spectrum immunosuppressants; however, there is a lack of effective targeted medications, resulting in generally poor therapeutic outcomes. Regarding the development of JAK inhibitors, the first used was the fungal extract Tofacitinib, followed by Ruxolitinib, which was developed based on Tofacitinib, and Baricitinib, which has a similar structure to Ruxolitinib. Regarding AA treatments, the only approved medication includes Baricitinib and Ritlecitinib. Besides Ivarmacitinib, Zelgen's Jaktinib reached its Phase III primary endpoint in June 2024 for alopecia areata; AbbVie's Upadacitinib is in Phase III clinical trials. According to statistics, the global market size for AA reached USD $7.1 billion in 2021. Frost & Sullivan projects that the hair loss market in China will reach RMB 41.2 billion by 2026, with an annual compound growth rate of nearly 12%. About Hengrui Pharmaceuticals Last month, Hengrui Pharmaceuticals announced its performance for the first half of 2024: the company achieved a revenue of 13.601 billion yuan, a year-on-year increase of 21.78%. Of this, income from innovative drugs reached 6.612 billion yuan, marking a 33.25% increase compared to the previous year, with licensing income amounting to 160 million euros. In 2024 H1, the net profit attributable to shareholders of the listed company was 3.432 billion yuan, up 48.67% year-on-year; the net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 3.490 billion yuan, a 55.58% increase year-on-year. Since the implementation of centralized procurement in 2021, the company’s semi-annual revenue has never exceeded the peak of 13.3 billion yuan in 2021; this exceptional performance indicates that the company has finally overcome the impact of centralized procurement and re-entered a high growth trajectory. The company continues to refine its established platforms including mature chemical medicines (including peptides, PROTAC), mono/dual antibody drugs, ADCs, small nucleic acids, nuclear medicine, multispecific antibodies, and dual-antibody ADC platforms. Moreover, it has started to build new molecular platforms such as PDC, AOC, DAC, mRNA, and continues to develop platforms in structural biology and AI drug research. Currently, a total of 18 innovative drugs and indications are in the NDA phase, with over 10 ADC pipeline products in research. In addition, the company’s efforts in taking innovative drugs international have been fruitful, becoming the second engine of revenue growth. To date, Hengrui has authorized 11 innovative drug projects internationally, with a total overseas amount of 10.35 billion USD and an upfront payment of 315 million USD. How to obtain the latest research advancements in the field of biopharmaceuticals? In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

09 Sep 2024

·www.biospace.com

The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market

While reported use of Sanofi/Regeneron’s Dupixent has declined with the adoption of LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the overall population receiving advanced treatments is on the rise, according to Spherix Global Insights. EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market. However, the introduction of LEO Pharma’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq has started to disrupt the treatment landscape. While Dupixent still holds the highest market share by a significant margin, its dominance is gradually diminishing with the rising adoption of these newer treatments and is expected to continue declining as additional therapies emerge. Spherix Global Insights has been closely monitoring the AD market since before Dupixent’s launch, providing quarterly updates through the RealTime Dynamix™ service. The latest quarterly results indicate that despite a mixed initial reception, Adbry has significantly grown and now competes closely with Rinvoq, whose usage has plateaued since 2022. Despite the evolution of the treatment landscape, results from the study also reveal dermatologist (n=105) estimates of the adult population receiving advanced systemic treatments have grown over the past two years, now capturing two-fifths of adult atopic dermatitis patients. This growth highlights the increasing demand for effective AD treatments and underscores the need for new options in the market. With a growing pipeline and increased competition, manufacturers will need to differentiate their assets. According to Spherix’s latest quarterly report, specific efficacy attributes including itch reduction as well as mechanism of action are considered key differentiators, both of which Galderma’s nemolizumab brings to the market. Further, physicians report the highest unmet needs for patients on a second-line advanced systemic and those with severe itch, two patient types manufacturers are keen to capture. The potential approvals of Galderma’s nemolizumab and Eli Lilly’s lebrikizumab are poised to further shift physician perceptions. Preference for the IL-13 mechanism has been steadily declining over the past few years in favor of the IL-31 mechanism, now on par with JAK inhibitors. As such, the percentage of dermatologists that prefer nemolizumab to gain FDA approval is more than double that of lebrikizumab, however, dermatologists are anticipating adopting both therapies at the expense of Dupixent. Of note, the potential adoption of nemolizumab is further supported by the anticipated prescriber experience from nemolizumab’s recent approval for prurigo nodularis , a skin condition characterized by chronic itch. Spherix Global Insights remains dedicated to tracking these developments, offering critical insights into the evolving atopic dermatitis market and guiding stakeholders through the shifting treatment landscape. RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit  spherixglobalinsights.com  or connect through  LinkedIn .  For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:  NOTICE : All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement. CONTACT: Gianna Melendez, Dermatology Franchise Head Spherix Global Insights 4848794284 gianna.melendez@spherixglobalinsights.com

Drug Approval

100 Deals associated with Abrocitinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11400	Abrocitinib	D11AH	DB14973

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	United Kingdom	Pfizer Inc.	08 Sep 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Eczema	Phase 3	United States	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	China	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Argentina	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Belgium	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Brazil	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Bulgaria	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Canada	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Chile	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Germany	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Israel	Pfizer Inc.	11 Jun 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


JADE MONO-1, MONO-2, TEEN, REGIMEN, EXTEND (Pubmed \| Allergy)	Phase 3	Moderate Atopic Dermatitis	-	Abrocitinib 200mg	hegvatkjpd(qqbscvmkwi) = oeupllggqc qfkpxrdchp (jaicxdizvn ) View more	Positive	03 Mar 2025
				Abrocitinib 100mg	hegvatkjpd(qqbscvmkwi) = jkencjjmfu qfkpxrdchp (jaicxdizvn ) View more
NCT03575871 \| NCT03349060 \| NCT02780167 \| NCT03720470 \| NCT03796676 \| NCT02201524 \| NCT03627767 (JADE MONO-1 \| MONO-2 \| COMPARE \| TEEN \| psoriasis trial \| REGIMEN, Pubmed)	Phase 3	Severe Atopic Dermatitis	453	Abrocitinib 100 mg	ojgzulxoro(vmokbkessj) = oadqewpesk sbmidbnmew (ayrvawjqmu ) View more	Positive	19 Jun 2024
NCT05038982 (Pubmed)	Phase 2	prurigo nodularis \| Pruritus	25	Abrocitinib 200 mg	bhfvknrqyx(ckcpzsbvhi) = ogoujvdcsx mqzlkovulq (mqexpcrcop, -118.5 to -38.1) View more	Positive	05 Jun 2024
				Placebo	bhfvknrqyx(ckcpzsbvhi) = fcdwfxakyi mqzlkovulq (mqexpcrcop, -98.8 to -8.6) View more
NCT05067439 (CTgov)	Phase 1	-	26	Omeprazole+Efavirenz+Caffeine (Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)	tjszdjzefv(lrezmpkwid) = paqcsazwah wohocgscbg (duruwdwozy, 101) View more	-	31 May 2024
				Omeprazole+Efavirenz+Abrocitinib+Caffeine (Abrocitinib 200 mg QD + Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)	tjszdjzefv(lrezmpkwid) = qvpoavmnws wohocgscbg (duruwdwozy, 90) View more
NCT03575871 \| NCT03422822 \| NCT03349060 \| NCT02780167 \| NCT03720470 (Pubmed \| Skin Health Dis) Manual	Phase 2/3	Dermatitis, Atopic	-	Abrocitinib 100 mg	zkaqanterw(gkdjkmvwwi) = ihddgymnoh erwphabqgh (hhycfixryq ) View more	Positive	05 May 2024
				Abrocitinib 200 mg	zkaqanterw(gkdjkmvwwi) = rrkygkmczr erwphabqgh (hhycfixryq ) View more
NCT04345367 (JADE DARE, EADV2023)	Phase 3	Moderate Atopic Dermatitis	727	Abrocitinib 200 mg	lbyjgqtlln(awejhkjlag) = For the most stringent EASI categories ( EASI 90-99 and EASI-100 ) , and at all 3 visits, this effect was more pronounced with abrocitinib than with dupilumab ynvbcjtxdw (qrkchaehni )	-	11 Oct 2023
				Dupilumab 300 mg
NCT03915496 (JADE MOA, EADV2023)	Phase 2	Moderate Atopic Dermatitis IL-6 \| IFNGR1/2 \| MX1 ... View more	46	Abrocitinib 200 mg	bafzpumsnz(sbyafzhjtb) = tmxapghadb vungyjpvxs (legulietlx )	-	11 Oct 2023
				Abrocitinib 100 mg	bafzpumsnz(sbyafzhjtb) = pkydjbhfvx vungyjpvxs (legulietlx )
NCT04345367 (JADE DARE, EADV2023)	Phase 3	Moderate Atopic Dermatitis	727	Abrocitinib 200 mg QD	kpiwdpjzve(eqxtfgbbje) = mwzdrnuagn wmjffafaft (ybbbbuxasl )	Positive	11 Oct 2023
				Dupilumab 300 mg Q2W	kpiwdpjzve(eqxtfgbbje) = yltgtnhcei wmjffafaft (ybbbbuxasl )
NCT03422822 (JADE EXTEND, EADV2023)	Phase 3	Moderate Atopic Dermatitis	-	Abrocitinib 200 mg	onyymgmdpc(qnmwxchogd) = rewtzdmyxm lexfzctkon (vugvebnmvv )	Positive	11 Oct 2023
				Abrocitinib 100 mg	onyymgmdpc(qnmwxchogd) = qrerjrysrm lexfzctkon (vugvebnmvv )
EADV2023	Not Applicable	Dermatitis, Atopic	90	Abrocitinib	acvaovhxxb(pugcboxtrc) = 23 ( 0.85/patient year ( PY )) yrmabwrwhe (qvhmeeaitz ) View more	-	11 Oct 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis